Bitfarms (BITF) CEO confirms plan to liquidate all BTC holdings, transition to AI data centers, and rebrand as Keel Infrastructure by April 2026.
Browsing: Stocks
Snap (SNAP) surged 13% after Irenic Capital revealed a 2.5% stake and urged CEO Evan Spiegel to cut costs, pivot to AI, and reconsider Spectacles.
Super Micro Computer (SMCI) stock crashes 65% from peak as co-founder faces export violation charges. Major investors exit despite AI infrastructure growth.
U.S. stocks rallied sharply Tuesday with Dow up 1,000 points as Iran and the U.S. signaled potential end to military conflict. Oil prices dropped on the news.
Meta (META) stock rises 4% after unveiling two prescription Ray-Ban smart glasses at $499 with AI translation and nutrition tracking features.
Amazon (AMZN) partners with Delta Air Lines to bring Leo satellite internet to 500 planes by 2028, competing directly with SpaceX’s Starlink service.
NIO (NIO) stock gains 3.8% after launching its first Americas showroom in San José, Costa Rica. Q1 deliveries of 80K-83K vehicles expected Wednesday.
ARK Invest sold $87M+ in Nvidia and Meta shares last week, while buying Circle Internet and CoreWeave in a strategic portfolio rebalancing move.
The Walmart Recession Signal has reached 2008 crisis levels as WMT outperforms luxury stocks, potentially warning of economic slowdown ahead.
Nike (NKE) reports Q3 FY26 earnings today. Options traders expect 8-9% move. China weakness, margins, and CEO turnaround plan in focus.
Bernstein upgrades Western Digital and raises Seagate and Sandisk targets after TurboQuant-driven selloff, calling the market reaction overdone.
Wells Fargo reduces S&P 500 target to 7,300 amid Iran conflict and stagflation worries. Markets price war risk higher than oil for the first time.
Boston Scientific (BSX) shares fell 9% to two-year lows after Watchman trial data revealed elevated stroke rates and Raymond James downgraded the stock.
Oklo (OKLO) dropped 9% following a Q4 earnings miss as insiders sold over $100M in shares. UBS and Goldman Sachs reduced price targets on execution concerns.
Apellis Pharmaceuticals (APLS) stock jumped 136% after Biogen announced a $5.6B acquisition deal at $41/share, marking a 140% premium to closing price.